After ‘transformative’ year, Roivant aims to challenge bigger rivals in inflammation and immunology

Roivant shares gain more than 10% after narrower-than-expected quarterly loss.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.